The 10 highest value R&D projects in biopharma

The world’s pharmaceutical companies are set to invest $302 billion in R&D by 2028—but what will they get in return?

A new annual report from Evaluate names the assets currently in the pipeline that have the highest value potential, from Merck & Co.’s sotatercept and Novartis’ iptacopan to biotech challenger Madrigal Pharmaceuticals' nonalcoholic steatohepatitis drug that's making waves.